Literature DB >> 23741253

miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer.

Yan Guo1, Huihui Liu, Hui Zhang, Chao Shang, Yongsheng Song.   

Abstract

Transitional cell carcinoma (TCC) is one of the most common types of malignancies and a leading cause of genitourinary system cancer mortality worldwide. The tumor suppressor gene FOXO1, a member of the forkhead box O (FOXO) subfamily of transcription factors, is downregulated in a number of cancers, including TCC; however, the underlying mechanisms are poorly understood. In the present study, we used microRNA (miRNA) target prediction algorithms to identify a conserved potential miR-96 binding site in the 3'-untranslated region (3'-UTR) of FOXO1. Using quantitative real-time PCR (qRT-PCR) and northern blot analysis, we identified that miR-96 was downregulated in TCC tissues compared to normal bladder tissues (NB), suggesting that the loss of FOXO1 expression in TCC may be mediated by miR-96. To confirm this, we transfected pre-miR-96/anti-miR-96 into the T24 TCC cell line and revealed that miR-96 expression was sufficient to significantly reduce FOXO1 expression. Conversely, FOXO1 expression was not completely restored by the inhibition of miR-96 in T24 cells. Moreover, RNA silencing of FOXO1 significantly reduced miR-96 inhibitor-mediated T24 cell apoptosis. In conclusion, our study demonstrates that the miR-96 targeting of FOXO1 is upregulated in TCC; in addition, TCC tumorigenesis may be partly due to the ability of miR-96 to promote FOXO1 repression, thereby bypassing cell apoptosis controls.

Entities:  

Keywords:  apoptosis; bladder transitional cell carcinoma; forkhead box protein O1; miR-96

Year:  2012        PMID: 23741253      PMCID: PMC3673640          DOI: 10.3892/ol.2012.775

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer.

Authors:  Stephen S Myatt; Jun Wang; Lara J Monteiro; Mark Christian; Ka-Kei Ho; Luca Fusi; Roberto E Dina; Jan J Brosens; Sadaf Ghaem-Maghami; Eric W-F Lam
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

3.  MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression.

Authors:  Xiang Fei; Manlong Qi; Bin Wu; Yongsheng Song; Yueping Wang; Tingting Li
Journal:  FEBS Lett       Date:  2012-01-16       Impact factor: 4.124

4.  Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.

Authors:  Haojie Huang; Kevin M Regan; Fang Wang; Diping Wang; David I Smith; Jan M A van Deursen; Donald J Tindall
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-24       Impact factor: 11.205

5.  MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Koji Ueno; Varahram Shahryari; Z Laura Tabatabai; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-11-01       Impact factor: 4.944

6.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells.

Authors:  Irene K Guttilla; Bruce A White
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

8.  Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1.

Authors:  Anna V Hoekstra; Erin C Ward; Jennifer L Hardt; John R Lurain; Diljeet K Singh; Barbara M Buttin; Julian C Schink; J Julie Kim
Journal:  Gynecol Oncol       Date:  2008-01-29       Impact factor: 5.482

9.  HLA-B gene participates in the NF-kappaB signal pathway partly by regulating S100A8 in the laryngeal carcinoma cell line Hep2.

Authors:  Yan Guo; Jia Liu; Zhenming Xu; Kailai Sun; Weineng Fu
Journal:  Oncol Rep       Date:  2008-06       Impact factor: 3.906

Review 10.  Epidemiology of urinary bladder cancer: from tumor development to patient's death.

Authors:  Cristiane Murta-Nascimento; Bernd J Schmitz-Dräger; Maurice P Zeegers; Gunnar Steineck; Manolis Kogevinas; Francisco X Real; Núria Malats
Journal:  World J Urol       Date:  2007-06       Impact factor: 3.661

View more
  39 in total

1.  MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.

Authors:  Hong-Ming Song; Yi Luo; Deng-Feng Li; Chuan-Kui Wei; Kai-Yao Hua; Jia-Lu Song; Hui Xu; Niraj Maskey; Lin Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.

Authors:  Emmanuel I Papadopoulos; George M Yousef; Andreas Scorilas
Journal:  Tumour Biol       Date:  2015-04-02

3.  Regulation of growth of human bladder cancer by miR-192.

Authors:  Yongchao Jin; Jiasun Lu; Jiling Wen; Yinzhou Shen; Xiaofei Wen
Journal:  Tumour Biol       Date:  2015-01-09

4.  miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells.

Authors:  Jun-Jie Yu; Yin-Xia Wu; Fu-Jun Zhao; Shu-Jie Xia
Journal:  Med Oncol       Date:  2014-03-15       Impact factor: 3.064

Review 5.  Posttranscriptional regulation of FOXO expression: microRNAs and beyond.

Authors:  P Urbánek; L-O Klotz
Journal:  Br J Pharmacol       Date:  2016-05-02       Impact factor: 8.739

6.  Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1.

Authors:  Guanghua Liu; Xin Zhao; Jingmin Zhou; Xiangming Cheng; Zixing Ye; Zhigang Ji
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

7.  Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.

Authors:  Emmanuel I Papadopoulos; Andreas Scorilas
Journal:  Clin Transl Sci       Date:  2015-09-10       Impact factor: 4.689

Review 8.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

Review 9.  FOXO transcription factors in cancer development and therapy.

Authors:  Alexandra Coomans de Brachène; Jean-Baptiste Demoulin
Journal:  Cell Mol Life Sci       Date:  2015-12-19       Impact factor: 9.261

10.  MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells.

Authors:  Haizhou Guo; Qianping Li; Weihao Li; Tianliang Zheng; Song Zhao; Zhangsuo Liu
Journal:  Mol Cell Biochem       Date:  2014-01-29       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.